← All organizations

Nichi-Iko Pharmaceutical Co., Ltd.

For profitWebsite ↗

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

Last known activity

Mar 26, 2026

Timeline

1960s

Jul 15, 1965
Nichi-Iko Pharmaceutical Co., Ltd.— Founded

2010s

Jul 11, 2016
Sagent Pharmaceuticals, Inc.— Acquired
Sep 12, 2017
daptomycin— NDA Secondary Org
Dec 1, 2017
thiamine— Marketing Organization

Drugs by trial phase (6 distinct, 6 trials)

Phase 4 (0 own, 4 via acquisition)

Phase 3 (1 own, 0 via acquisition)

infliximab

Phase 2 (0 own, 1 via acquisition)

camostat mesylate

Indications

Studied for

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Sagent Pharmaceuticals, Inc.

Recent trials (4)

NCT02990806Lead sponsorPhase 3Dec 1, 2016
NCT01931189Lead sponsorPhase 1Aug 1, 2013
NCT01927263Lead sponsorPhase 3Jul 1, 2013
NCT01567358Lead sponsorPhase 1Feb 1, 2012

Details

Founded: Toyama, JP Jul 15, 1965
Last known activity: Mar 26, 2026